Ilana Gareen
Ilana F Gareen is an American epidemiologist who is a professor at Brown University. Her research considers the development and implementation of new imaging technologies. She was co-chair of the National Lung Screening Trial.
Early life and education
Gareen completed her undergraduate degree in bioethics at Vassar College. She moved to Yale University for a Master's in Public Health, where she studied the prevalence of HIV/AIDS in New York City inmates.[1] After her graduate studies, she worked as a research associate at Cornell University, focusing on epidemiology. She earned her doctorate at University of California, Los Angeles, where she investigated reproductive and perinatal epidemiology.[2]
Research and career
Gareen joined Brown University as a research fellow in 1997, was made assistant professor in 1999 and full professor in 2025. She develops strategies for diagnostic imaging, with a focus on patient outcomes and quality of life.
Gareen was co-chair of the National Lung Screening Trial. She looked at how significant incidental finding detection impacted patient morbidity.[3] Her research has shown that 30% of low dose CT scans contain significant incidental findings, and 90% of them were considered reportable. The most common were emphysema, coronary artery calcium and masses.[4] The National Lung Screening Trial demonstrated that screening with low dose CT scans reduced lung cancer mortality compared to chest radiography.[5] CT scans are much more costly than X-rays, but have a better impact on quality of life.[6]
Selected publications
- Denise R Aberle; Amanda M Adams; Christine D Berg; et al. (4 August 2011). "Reduced lung-cancer mortality with low-dose computed tomographic screening". The New England Journal of Medicine. 365 (5): 395–409. doi:10.1056/nejmoa1102873. ISSN 0028-4793. PMC 4356534. PMID 21714641. Wikidata Q28241954.
- William C Black; Ilana F Gareen; Samir S Soneji; et al. (1 November 2014). "Cost-effectiveness of CT screening in the National Lung Screening Trial". The New England Journal of Medicine. 371 (19): 1793–1802. doi:10.1056/nejmoa1312547. ISSN 0028-4793. PMC 4335305. PMID 25372087. Wikidata Q35104187.
- Gil D Rabinovici; Constantine Gatsonis; Charles Apgar; et al. (1 April 2019). "Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia". JAMA. 321 (13): 1286–1294. doi:10.1001/jama.2019.2000. ISSN 0098-7484. PMC 6450276. PMID 30938796. Wikidata Q92784324.
References
- ↑ "AIDS in New York City prisoners | WorldCat.org". search.worldcat.org. Retrieved 2025-09-13.
- ↑ "Three applications in reproductive and perinatal epidemiology : use of intrauterine device and pelvic inflammatory disease : maternal age and cesarean delivery : and neonatal outcomes of cesarean delivery | WorldCat.org". search.worldcat.org. Retrieved 2025-09-13.
- ↑ "Ilana Gareen, PhD, MPH, AB | PCORI". www.pcori.org. 2020-09-10. Retrieved 2025-09-13.
- ↑ "Nearly 90% of significant incidental findings on lung cancer screenings are considered reportable". healthimaging.com. 2023-05-10. Retrieved 2025-09-13.
- ↑ Black, William C.; Gareen, Ilana F.; Soneji, Samir S.; Sicks, JoRean D.; Keeler, Emmett B.; Aberle, Denise R.; Naeim, Arash; Church, Timothy R.; Silvestri, Gerard A.; Gorelick, Jeremy; Gatsonis, Constantine (2014-11-06). "Cost-Effectiveness of CT Screening in the National Lung Screening Trial". New England Journal of Medicine. 371 (19): 1793–1802. doi:10.1056/NEJMoa1312547. ISSN 0028-4793. PMC 4335305. PMID 25372087.
- ↑ "Is CT Screening For Lung Cancer Cost-Effective". www.meddeviceonline.com. Archived from the original on 2014-11-22. Retrieved 2025-09-13.